We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Fibrogen Inc (FGEN) USD0.01

Sell:$1.88 Buy:$1.89 Change: $0.20 (11.37%)
NASDAQ:2.96%
Market closed |  Prices as at close on 22 February 2024 | Switch to live prices |
Sell:$1.88
Buy:$1.89
Change: $0.20 (11.37%)
Market closed |  Prices as at close on 22 February 2024 | Switch to live prices |
Sell:$1.88
Buy:$1.89
Change: $0.20 (11.37%)
Market closed |  Prices as at close on 22 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing a pipeline of therapeutics. It applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase activity for the treatment of anemia caused by chronic kidney disease (CKD). It is also developing Roxadustat for anemia associated with myelodysplastic syndromes. It also develops Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. Its Roxadustat is approved in China, Europe and Japan for the treatment of anemia in CKD.

Contact details

Address:
409 ILLINOIS STREET
SAN FRANCISCO
94158
United States
Telephone:
+1 (415) 9781200
Website:
https://www.fibrogen.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
FGEN
ISIN:
US31572Q8087
Market cap:
$177.01 million
Shares in issue:
98.34 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Thane Wettig
    Chief Executive Officer, Director, Chief Commercial Officer
  • Juan Graham
    Chief Financial Officer
  • Christine Chung
    Senior Vice President, China Operations

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.